Loading
Spain's public health research institute. It created the CIBER research networks, including the cancer network CIBERONC, and funds academic trials such as Barcelona's CAR-T studies.
The Instituto de Salud Carlos III is Spain's public biomedical and health research body. The CIBER consortium describes itself as a public research consortium created on the initiative of the ISCIII, dating from 2006, and it added cancer as a thematic area, CIBERONC, on 1 January 2017. The ISCIII is listed on ClinicalTrials.gov as a collaborator on CART19-BE-01, the trial behind the academic CAR-T ARI-0001, and is named first among the funders of CARTBCMA-HCB-01, the trial of the academic BCMA CAR-T ARI0002h.
The ISCIII's own website returned a maintenance page on 3 November 2026, so this record does not describe its budget, its centres or its funding calls; those are named as a gap on the Spain page.
Shares CARTBCMA-HCB-01 (ARI0002h BCMA CAR-T, Hospital Clínic de Barcelona), Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study, CART19-BE-01 (ARI-0001 CAR-T, Hospital Clínic de Barcelona).
Shares CARTBCMA-HCB-01 (ARI0002h BCMA CAR-T, Hospital Clínic de Barcelona), Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study, CART19-BE-01 (ARI-0001 CAR-T, Hospital Clínic de Barcelona).
Shares CARTBCMA-HCB-01 (ARI0002h BCMA CAR-T, Hospital Clínic de Barcelona), Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study.
Shares CIBERONC (Centro de Investigación Biomédica en Red de Cáncer), CART19-BE-01 (ARI-0001 CAR-T, Hospital Clínic de Barcelona).
Shares CIBERONC (Centro de Investigación Biomédica en Red de Cáncer), CARTBCMA-HCB-01 (ARI0002h BCMA CAR-T, Hospital Clínic de Barcelona), Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study, CART19-BE-01 (ARI-0001 CAR-T, Hospital Clínic de Barcelona).
Shares CARTBCMA-HCB-01 (ARI0002h BCMA CAR-T, Hospital Clínic de Barcelona), Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study, CART19-BE-01 (ARI-0001 CAR-T, Hospital Clínic de Barcelona).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/